Royalty Pharma Reports First Quarter 2025 Results

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12$596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to$3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “Our business momentum continued in the first quarter of 2025 as we delivered double- ...